The hype has faded, but don’t count out convalescent plasma in COVID battle
The once-promising therapy has suffered setbacks, but some proponents say it’s too early to abandon the treatment
The once-promising therapy has suffered setbacks, but some proponents say it’s too early to abandon the treatment